Search

Your search keyword '"Auerswald, G"' showing total 365 results
Start Over Author "Auerswald, G"
365 results on '"Auerswald, G"'

84. Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect

Author

Morfini, M, Batorova, A, Mariani, G, Auerswald, G, Bernardi, Francesco, Di Minno, G, Dolce, A, Fede, C, Giansily Blaizot, M, Ingerslev, J, Martinowitz, U, Napolitano, M, Pinotti, Mirko, Schved, Jf, International FVII [IF7], Seven Treatment Evaluation Registry [STER] Study Groups, Morfini, M, Batorova, A, Mariani, G, Auerswald, G, Bernardi, F, DI MINNO, Giovanni, Dolce, A, Fede, C, Giansily Blaizot, M, Ingerslev, J, Martinowitz, U, Napolitano, M, Pinotti, M, Schved, Jf, Morfini M, Batorova A, Mariani G, Auerswald G, Bernardi F, Di Minno G, Dolce A, Fede C, Giansily-Blaizot M, Ingerslev J, Martinowitz U, Napolitano M, Pinotti M, and Schved JF.

Subjects
Heredity, Pharmacokinetic, inherited Factor VII deficiency, Factor VII Deficiency, Socio-culturale, Factor VIIa, Pharmacology, Severity of Illness Index, Pharmacokinetics, Predictive Value of Tests, hemic and lymphatic diseases, Humans, Medicine, Genetic Predisposition to Disease, FVII deficiency, Registries, cardiovascular diseases, Blood Coagulation, Volume of distribution, biology, Coagulants, business.industry, Vascular biology, rFVIIa, Hematology, Factor VII, Recombinant Proteins, Phenotype, Treatment Outcome, pharmacokinetics, Recombinant factor VIIa, Pharmacodynamics, biology.protein, Blood Coagulation Tests, Steady state (chemistry), Drug Monitoring, business
Abstract

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect

Published
2014

87. Invasive procedures and minor surgery in factor VII deficiency

Author

Mariani,G, Dolce, A, Ingerslev, J, Giansily Blaizot, M, DI Minno, MD, Auerswald, G, DE Saez, AR, Tagliaferri, A, Batorova, A., NAPOLITANO, Mariasanta, Mariani, Guglielmo, Dolce, A., Napolitano, M., Ingerslev, J., Giansily Blaizot, M., DI MINNO, Matteo, Auerswald, G., De Saez, A. R., Tagliaferri, A., Batorova, A., Mariani,G, Dolce, A, Napolitano, M, Ingerslev, J, Giansily-Blaizot, M, DI Minno, MD, Auerswald, G, DE Saez, AR, Tagliaferri, A, and Batorova, A

Subjects
Adult, Male, MINOR SURGERY, INVASIVE PROCEDURES, FACTOR VII DEFICIENCY, Adolescent, Factor VII Deficiency, Blood Loss, Surgical, Infant, Hemorrhage, Hematology, Factor VII, Hemostasi, Middle Aged, Settore MED/15 - Malattie Del Sangue, Minor Surgical Procedure, Young Adult, Coagulant, Child, Preschool, Surgical Procedures, Operative, Female, Child, Genetics (clinical), Aged, Human
Published
2012

88. Bleeding symptoms at disease presentation and prediction of ensuing bleeding in inherited FVII deficiency

Author

Di Minno, M., Dolce, A., Mariani, G., STER Study Group, Auerswald, G, Batorova, A, Bernardi, F, Di Minno, G, M. N. Di Minno, Dolce, A, Giansilly Balizot, M, Ingerslev, J, Mariani, G, Martinowitz ,U, Morfini, M, Pinotti, M, Shapiro, A, Schved, JF, Sørensen, B., NAPOLITANO, Mariasanta, Di Minno, M., Dolce, A., Mariani, G.,STER Study Group, Auerswald, G, Batorova, A, Bernardi, F, Di Minno, G, M N Di Minno, Dolce, A, Giansilly-Balizot, M, Ingerslev, J, Mariani, G, Martinowitz ,U, Morfini, M, Napolitano, M, Pinotti, M, Shapiro, A, Schved, JF, Sørensen, B., DI MINNO, Matteo, Dolce, Alberto, and Mariani, Guglielmo

Subjects
Registrie, Male, Pediatrics, Factor VII Deficiency, International Cooperation, Asymptomatic individual, 030204 cardiovascular system & hematology, chemistry.chemical_compound, 0302 clinical medicine, Retrospective Studie, Age Factor, Registries, Young adult, Child, Clinical Trials as Topic, Hematology, Factor VII, Age Factors, Middle Aged, Phenotype, Treatment Outcome, Child, Preschool, Female, Presentation (obstetrics), medicine.symptom, Human, Adult, Quality Control, Risk, medicine.medical_specialty, Adolescent, Hemorrhage, Asymptomatic, Major bleed, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, Retrospective Studies, Models, Statistical, business.industry, Minor bleed, Infant, Retrospective cohort study, chemistry, Disease Presentation, Relative risk, business, 030215 immunology
Abstract

SummaryIndividuals with inherited factor VII (FVII) deficiency display bleeding phenotypes ranging from mild to severe, with 30% of patients having always been asymptomatic (non-bleeding). In 626 FVII-deficient individuals, by analysing data from the International Factor VII (IF7) Registry and the Seven Treatment Evaluation Registry (STER), we determined whether bleeding type at disease presentation and FVII coagulant activity (FVIIc) predict ensuing bleeds. At disease presentation/diagnosis, 272 (43.5%) individuals were non-bleeding, 277 (44.2%) had minor bleeds, and 77 (12.3%) had major bleeds. During a median nine-year index period (IP) observation, 87.9% of non-bleeding individuals at presentation remained asymptomatic, 75.1% of minor-bleeders had new minor bleeds, and 83.1% of major-bleeders experienced new major bleeds. After adjusting for FVIIc levels and other clinical and demographic variables, the relative risk (RR) for ensuing bleedings during the IP was 6.02 (p

Published
2012

90. Factor VII deficiency: evidence that in minor surgery one-day replacement therapy is sufficient

Author

Mariani, G, Dolce, A, Ingerslev, J, Batorova, A, Schved, JF, Di Minno, G, Auerswald, G, Giansilly Blaizot,M, Aronis, S, Ruiz de Saez, A, Tagliaferri, A., NAPOLITANO, Mariasanta, SIRAGUSA, Sergio, Mariani, G, Dolce, A, Ingerslev, J, Batorova, A, Napolitano, M, Schved, JF, Di Minno, G, Auerswald, G, Giansilly-Blaizot,M, Aronis, S, Siragusa, S, Ruiz de Saez, A, and Tagliaferri, A

Subjects
Inherited FACTOR VII DEFICIENCY, MINOR SURGERY, INVASIVE PROCEDURES, Settore MED/15 - Malattie Del Sangue
Published
2011

91. Replacement Therapy for Minor Surgery and Invasive Procedures in Factor VII Deficiency: The STER Experience

Author

Napolitano, M., Dolce, A., Ingerslev, J., Giansily-blaizot, M., Minno, M., Auerswald, G., Saez, A., Batorova, A., Caimi, T., Chuansumrit, A., Fernandez, M., Bertrand, M., Verdy, E., Zanon, E., Abecassis, L., Aronis, S., Siragusa, S., Orecchioni, A., Mariani, G., Napolitano, M., Dolce, A., Ingerslev, J., Giansily-Blaizot, M., Minno, M., Auerswald, G., Saez, A., Batorova, A., Caimi, T., Chuansumrit, A., Fernandez, M., Bertrand, M., Verdy, E., Zanon, E., Abecassis, L., Aronis, S., Siragusa, S., Orecchioni, A., and Mariani, G.

Subjects
Adverse events, Inherited Factor VII deficiency
Published
2011

93. Comunicazione orale

Author

Di Minno, M., Batorova, A., Dolce, A., Minno, G., Bernardi, F., Schved, J., Ingerslev, J., Giansily Blaizot, M., Auerswald, G., Mariani, G., NAPOLITANO, Mariasanta, Di Minno, M., Batorova, A., Napolitano, M., Dolce, A., Minno, G., Bernardi, F., Schved, J., Ingerslev, J., Giansily-Blaizot, M., Auerswald, G., and Mariani, G.

Subjects
Bleeding Phenotype,Factor VII deficiency
Published
2011

98. Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies

Author

Napolitano, M., primary, Di Minno, M. N. D., additional, Batorova, A., additional, Dolce, A., additional, Giansily-Blaizot, M., additional, Ingerslev, J., additional, Schved, J.-F., additional, Auerswald, G., additional, Kenet, G., additional, Karimi, M., additional, Shamsi, T., additional, Ruiz de Sáez, A., additional, Dolatkhah, R., additional, Chuansumrit, A., additional, Bertrand, M. A., additional, and Mariani, G., additional

Published
2016
Full Text
View/download PDF

100. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study

Author

Gouw, S.C., Berg, H.M. van den, Fischer, K., Auerswald, G., Carcao, M., Chalmers, E., Chambost, H., Kurnik, K., Liesner, R., Petrini, P., Platokouki, H., Altisent, C., Oldenburg, J., Nolan, B., Garrido, R.P., Mancuso, M.E., Rafowicz, A., Williams, M., Clausen, N., Middelburg, R.A., Ljung, R., Bom, J.G. van der, PedNet, Res Determinants INhibitor Dev, AII - Amsterdam institute for Infection and Immunity, and Paediatric Infectious Diseases / Rheumatology / Immunology

Subjects
Adult, medicine.medical_specialty, congenital, hereditary, and neonatal diseases and abnormalities, Adolescent, Immunology, Hemorrhage, Hemophilia A, Biochemistry, Gastroenterology, Chemoprevention, Severity of Illness Index, Cohort Studies, Young Adult, Risk Factors, Internal medicine, hemic and lymphatic diseases, Severity of illness, medicine, Humans, Young adult, Child, Hematology, Factor VIII, Blood Coagulation Factor Inhibitors, Dose-Response Relationship, Drug, business.industry, Incidence (epidemiology), Hazard ratio, Cell Biology, Confidence interval, Surgery, Dose–response relationship, business, Cohort study
Abstract

The objective of this study was to examine the association of the intensity of treatment, ranging from high-dose intensive factor VIII (FVIII) treatment to prophylactic treatment, with the inhibitor incidence among previously untreated patients with severe hemophilia A. This cohort study aimed to include consecutive patients with a FVIII activity < 0.01 IU/mL, born between 2000 and 2010, and observed during their first 75 FVIII exposure days. Intensive FVIII treatment of hemorrhages or surgery at the start of treatment was associated with an increased inhibitor risk (adjusted hazard ratio [aHR], 2.0; 95% confidence interval [CI], 1.3-3.0). High-dose FVIII treatment was associated with a higher inhibitor risk than low-dose FVIII treatment (aHR, 2.3; 95% CI, 1.0-4.8). Prophylaxis was only associated with a decreased overall inhibitor incidence after 20 exposure days of FVIII. The association with prophylaxis was more pronounced in patients with low-risk F8 genotypes than in patients with high-risk F8 genotypes (aHR, 0.61, 95% CI, 0.19-2.0 and aHR, 0.85, 95% CI, 0.51-1.4, respectively). In conclusion, our findings suggest that in previously untreated patients with severe hemophilia A, high-dosed intensive FVIII treatment increases inhibitor risk and prophylactic FVIII treatment decreases inhibitor risk, especially in patients with low-risk F8 mutations.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results